Rugonersen
BP41674
Phase 1 small_molecule active
Quick answer
Rugonersen for Angelman Syndrome (AS) is a Phase 1 program (small_molecule) at Hoffmann-La Roche with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Hoffmann-La Roche
- Indication
- Angelman Syndrome (AS)
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- active